Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients
Brief Summary: A primary goal of this study is to investigate the significance of treatment duration, by comparing change after group psychotherapy of varying lengths. A secondary goal is to investigate the predictive value of selected patient variables on outcome: personality pathology, quality of object relations, presence of personality disorder, degree of initial disturbance, and education. One hundred and twenty patients from 5-6 different study sites (consisting of one coordinator and 3 therapists) will be included. Exclusion criteria are psychosis, substance abuse, and organically based symptoms. Patients are interviewed before treatment and one year after termination, and self-rated outcome measures are filled in at 3-month intervals during treatment and at termination. After an initial evaluation, patients are randomized to one of two manualized psychodynamic group psychotherapies with different treatment lengths (20 and 80 sessions). Each therapist will conduct both a short- and a long-term group, and sessions are taped in order to check treatment integrity.


Options:
A: Inclusion Criteria:

* Subject has primary diagnosis of Borderline Personality Disorder(BPD).
* Subject has Symptomatology of BPD for at least 1 year.
* Subject understands the study procedures and voluntarily agree to participate.
* Subject is able to read, understand and complete questionnaires.
* Subject agrees to use (2)acceptable forms of contraception throughout the study.
* Patient must have a screening SCL 90-R score of \> 120 (range 0-360).

Exclusion Criteria:

* Subject is not pregnant or breast feeding.
* Subject is unlikely to adhere to the study procedures and restrictions.
* Patient has failed treatment due to lack of efficacy of monoamine oxidase inhibitor(MAOI) medication.
* Patient anticipates need for surgery during the study.
* Patient has another predominant personality disorder other than BPD.
* Subject has an active history of substance abuse or dependence, e.g.,Positive Drug screen
* Subject has other health issues which could interfere with study interpretation.
* Subject reports recent suicide attempts or homicide attempts in the past 3 months.
* Subject must be substance abuse or dependence clean for (1) year.
* Subject has a history of a primary malignancy \< 5 yrs.
* Subject has a medical condition(s)that are excluded, per Protocol, or are unstable.
* Subject has abnormal screening laboratory values, per Protocol, or other clinically significant, unexplained laboratory abnormality.
* Subject is currently participating or has participated in a study within 30 days.
* Patient has donated blood products or has had phlebotomy of \> 300 ml within 8 weeks.
B: Inclusion Criteria:

* Patients who consult or are referred to oupatient psychiatric centers or private pratice, and who are considered suitable for ambulant psychodynamic group psychotherapy.

Exclusion Criteria:

* Active psychotic disorder, drug or alcohol dependence as main diagnosis, organically based symptoms, e.g. brain damage, autism and adult ADHD.
C: Inclusion Criteria:

1. female
2. 18-40 years
3. diagnosed BPD according to ICD-10 (F60.31) and SKID II
4. stable treatment
5. mastery of the German language
6. effective contraception
7. willingness to and acceptance of treatment with either botulinum toxin A or acupuncture

Exclusion Criteria:

1. Comorbid disorders of all ICD-10 groups o F0,

   * F1 (with exception of F1x.1),
   * F2,
   * F3 (with exception of 32.0 and F33.0),
   * F7 and disorders essentially defining the clinical picture from sections
   * F4,
   * F5,
   * F6.
2. Contraindication for treatment with botulinum toxin A according to the IMP's SmPC (e.g. myasthenia gravis, Lambert Eaton-syndrome or other impairments in neuromuscular function)
D: Inclusion Criteria:

* Patients must be of outpatient status at visit 1 and through visit 2.
* Patients must be 15 to 65 years of age at visit 1.
* Patients must meet all of the DSM-IV-TR General Diagnostic Criteria for a Personality Disorder and patients must meet DSM-IV-TR diagnostic criteria for BPD.
* The symptom severity as assessed by the total score of the ZAN-BPD, confirmed by a psychiatrist with training in the evaluation and assessment of BPD, must be greater than or equal to 9 at visit 2.
* Female patients of childbearing potential must test negative for pregnancy and must be using a medically accepted means of contraception throughout the course of the study.

Exclusion Criteria:

* Patients must not be investigators, study site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
* Persons employed by Lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
* Patients must not have previously participated (have been randomized) or withdrawn from this study or any other Lilly sponsored study investigating olanzapine.
* Patients must not have had previous treatment with olanzapine unless, in the opinion of the investigator, the patients' previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of olanzapine was confounded by concomitant medication.
* Female patients must not be pregnant or nursing.

Answer: B